Schizophrenic disorder treatment using combination therapy
Grant
US12594270B2
Kind: B2
Apr 07, 2026
Assignee
Cambridge Cognition Limited
Inventors
Kiri Granger, Jennifer Barnett
Abstract
The present specification disclose a combined therapy comprising one or more activators of an alpha-7 nicotinic acetylcholine receptor activity having 5-HT3 receptor inhibitory activity and one or more activators of 5-HT3 receptor activity for use in treating a schizophrenic disorder as well as methods of treating a schizophrenic disorder by administering a combined therapy comprising one or more activators of an alpha-7 nicotinic acetylcholine receptor activity having 5-HT3 receptor inhibitory activity and one or more activators of 5-HT3 receptor activity.
CPC Classifications
A61P 25/18
A61K 31/46
A61K 31/465
A61K 31/55
A61K 45/06
Filing Date
2020-10-21
Application No.
17755084
Claims
21